Alnylam Pharmaceuticals (ALNY) Net Cash Flow (2009 - 2026)

Alnylam Pharmaceuticals has reported Net Cash Flow for 18 years, with the latest figure at $60.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 53.46% year-over-year to $60.7 million; the trailing twelve-month figure through Mar 2026 stood at $676.4 million (up 105.72% YoY), and the FY2025 full-year result was $655.2 million, up 287.69% from the prior year.
• Net Cash Flow for Q1 2026 stood at $60.7 million, down from $171.7 million in the prior quarter.
• The five-year high for Net Cash Flow was $495.6 million in Q3 2022, with the low at -$283.7 million in Q1 2022.
• Historically, Net Cash Flow has averaged $51.7 million across 5 years, with a median of $50.3 million in 2022.
• Annual changes were most pronounced in 2022 — Net Cash Flow slumped 150.73% — and 2024, when it surged 2124.43%.
• Alnylam Pharmaceuticals' Net Cash Flow stood at -$208.5 million in 2022, then declined by 10.92% to -$231.2 million in 2023, then soared by 49.58% to -$116.6 million in 2024, then surged by 247.29% to $171.7 million in 2025, then plunged by 64.66% to $60.7 million in 2026.
• The last three Net Cash Flow figures came in at $60.7 million (Q1 2026), $171.7 million (Q4 2025), and $377.9 million (Q3 2025), per Business Quant data.